Pharma-Bio Serv, Inc.
PBSV · Services-Management Consulting Services · 22.9M shares · -0%/yr ↓ buyback · EDGAR filings ↗
Net buyback after stock comp: -$36K (gross $11K, SBC $48K)
Grade
D52gen composite 49pct→67; net + operating loss
Notable findings
- Cash burnNegative free cash flow (-0.2M)
- Net lossNet loss (net margin -1.1%)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
32.3%
Operating margin
-7.1%
Net margin
-1.1%
Return on equity
-0.8%
Return on assets
-0.7%
ROIC
-4.2%
Revenue growth (QoQ)
11.8%
Current ratio
7.7×
Free cash flow
-$222K
EBITDA
-$578K
Tangible book value
$12M
Cash & investments
$11M
Cash runway
196q
Stock comp / revenue
0.4%
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Pedro Lasanta | Officer | $176K FY2025 |
| Victor Sanchez | Officer | $246K FY2025 |
| Kirk Michel | Director | $56K FY2025 |
| Dov Perlysky | Director | $56K FY2025 |
| Howard Spindel | Director | $56K FY2025 |
| Irving Wiesen | Director | $56K FY2025 |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 10-Q | 2026-06-15 | 2026-04-30 | 0001654954-26-005986 ↗ |
| 8-K | 2026-06-15 | 2026-06-15 | 0001654954-26-005989 ↗ |
| 8-K | 2026-05-15 | 2026-05-15 | 0001654954-26-005006 ↗ |
| DEF 14A | 2026-04-16 | 2026-04-15 | 0001654954-26-003617 ↗ |
| 8-K | 2026-03-17 | 2026-03-17 | 0001654954-26-002338 ↗ |
| 10-Q | 2026-03-17 | 2026-01-31 | 0001654954-26-002336 ↗ |
| 10-K/A | 2026-02-27 | 2025-10-31 | 0001654954-26-001674 ↗ |
| 10-K | 2026-01-29 | 2025-10-31 | 0001654954-26-000710 ↗ |
| 8-K | 2026-01-29 | 2026-01-29 | 0001654954-26-000712 ↗ |
| 8-K | 2025-09-15 | 2025-09-15 | 0001654954-25-010776 ↗ |
| 10-Q | 2025-09-15 | 2025-07-31 | 0001654954-25-010775 ↗ |
| 8-K | 2025-06-16 | 2025-06-16 | 0001654954-25-007011 ↗ |